An end-to-end precision medicine approach for matching cancer patients to clinical trials (original) (raw)

2015, Journal of Clinical Oncology

AI-generated Abstract

The paper presents an end-to-end precision medicine approach for matching cancer patients to clinical trials, highlighting the use of the KEW CancerPlex® NGS sequencing panel. Through the analysis of 200 cancer cases, it identifies the genetic mutations linked to responses to both FDA-approved and investigational therapies. The study concludes that larger gene panels increase the detection of actionable mutations, thereby enhancing patient treatment matching.